Track topics on Twitter Track topics that are important to you
This insightful conversation features Graeme Martin, CEO of Takeda Research Investment (TRI) the corporate venture arm of Takeda Pharmaceutical, the largest pharma company in Japan and among the largest in the world. Dr. Martin shares TRI’s plans to invest US$100 million seed money in a variety of early-stage innovative ventures, to help expand Takeda’s research horizons outside Japan. With a plan to invest in 4-5 new efforts a year, TRI hopes to eventually manage a steady state investment of about 20 companies that will include both minority investments and active, collaborative partnerships designed to create synergies with Takeda’s considerable R&D resources.
Original Article: Takeda Research Investment: Reaching Beyond the Land of the Rising SunNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...